The Global Minimal Residual Disease Testing Market size is expected to reach $2.7 billion by 2028, rising at a market growth of 14.2% CAGR during the forecast period.
Minimal residual disease (MRD) testing is performed to identify solid tumors or hematological malignancies. MRD tests are mostly utilized for the diagnosis of a residual diagnosis in research and clinical settings. Through this test, the oncologists receive individualized information on the effectiveness of the utilized therapy from the ongoing monitoring of leftover cancer cells during the core therapy and throughout the remission stage.
Consequently, MRD tests also affect the decision-making for the selection of efficient treatment that would result in the improvement of the therapeutic results. Additionally, these tests can accurately forecast the likelihood of potential disease relapse. The onset of hematological malignancies or blood cancers takes place in the bone marrow, where stem cells give rise to red blood cells (RBC), white blood cells (WBC), and platelets.
These diseases affect the proper generation and operation of blood cells. These malignancies form when the development of healthy blood cells is obstructed by the unchecked proliferation of abnormal cells, which interferes with the normal functions of healthy cells. MRD is also known as measurable residual testing, and its test methods are used to determine the efficacy of cancer treatment and the need to direct future treatment strategies.
Leukemia, lymphoma, and myeloma are the three blood malignancies for which MRD testing is most commonly utilized, while its usage for other diseases’ diagnoses is being researched. In addition, since the outcomes can be utilized to customize a patient’s therapy, these tests are often considered helpful in the development of customized medicine.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Rad Laboratories, Inc., Guardant Health, Inc., Invitae Corporation (ArcherDX, Inc.), Bio-Techne Corporation, F. Hoffmann-La Roche Ltd., ICON plc (MolecularMD Corporation), Natera, Inc., Sysmex Corporation, Laboratory Corporation of America Holdings, and Invivoscribe, Inc.
Minimal residual disease (MRD) testing is performed to identify solid tumors or hematological malignancies. MRD tests are mostly utilized for the diagnosis of a residual diagnosis in research and clinical settings. Through this test, the oncologists receive individualized information on the effectiveness of the utilized therapy from the ongoing monitoring of leftover cancer cells during the core therapy and throughout the remission stage.
Consequently, MRD tests also affect the decision-making for the selection of efficient treatment that would result in the improvement of the therapeutic results. Additionally, these tests can accurately forecast the likelihood of potential disease relapse. The onset of hematological malignancies or blood cancers takes place in the bone marrow, where stem cells give rise to red blood cells (RBC), white blood cells (WBC), and platelets.
These diseases affect the proper generation and operation of blood cells. These malignancies form when the development of healthy blood cells is obstructed by the unchecked proliferation of abnormal cells, which interferes with the normal functions of healthy cells. MRD is also known as measurable residual testing, and its test methods are used to determine the efficacy of cancer treatment and the need to direct future treatment strategies.
Leukemia, lymphoma, and myeloma are the three blood malignancies for which MRD testing is most commonly utilized, while its usage for other diseases’ diagnoses is being researched. In addition, since the outcomes can be utilized to customize a patient’s therapy, these tests are often considered helpful in the development of customized medicine.
COVID-19 Impact Analysis
The modifications to treatment occurred at a considerably slow pace owing to the pandemic’s urgency. As a result, the setup of optimal time points to assess the disease response and evaluate for relapse by measuring the minimal residual disease for the newer methods could not be adequately established. This further made the intensification of therapy challenging by not providing an apt description of the therapy’s duration and time points. Therefore, the COVID-19 pandemic had a negative effect on the minimal residual disease testing market.Market Growth Factors
Increasing Cases Of Hematological Malignancies Across The World
Since the past few decades, the incidences of hematological malignancies have risen significantly. This increase includes the rising prevalence of hematological cancer subtypes as well. For example, leukemia was the eleventh leading mortality-causing factor that was associated with cancer in 2018. According to the Surveillance, Epidemiology, and End Results (SEER) Program, the disease also accounted for around 3.2% of all new emerging cancer cases in 2022.Growing Use Of MRD Test Methods In The Diagnosis And Care Of Various Cancers
Since their development, minimal residual disease testing methods have become an essential part of the diagnosis of various blood cancers type. In acute lymphocytic leukemia (ALL), MRD tests are an integral part of routine testing. Several studies have also suggested that MRD tests are the most appropriate way to determine the appropriate treatment that would be extremely helpful for the first ALL therapy. These tests also help in the identification of patients that are at risk of relapse. Such factors aid in the expansion of the minimal residual disease testing market significantly.Market Restraining Factors
Complex And Strict Regulations Regarding The Application Of MRD Tests
Like any other treatment and diagnostic methods, the minimal residual disease testing methodologies are also subject to specific issues related to the usage and suitability of these tests. The issue varies according to the tests. For example, multiparameter flow cytometry tests include complex data visualization, and these tests are unable to detect cytogenetic characteristics. Therefore, the strict regulations, along with the drawbacks of MRD tests, hampers the expansion and growth of the minimal residual disease testing market.Technology Outlook
Based on technology, the minimal residual disease testing market is categorized into flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS), and other technologies. The polymerase chain reaction (PCR) segment garnered the highest revenue share in the minimal residual disease testing market in 2021. The growth of the segment is because of the high practicality and simplicity of the PCR diagnostic devices in minimal residual disease testing. In addition, the PCR diagnostic device kits offer increased accessibility to information with a higher degree of sensitivity.
Application Outlook
On the basis of application, the minimal residual disease testing market is divided into hematological malignancies, leukemia, lymphoma, solid tumors, and other applications. The hematological malignancies segment acquired the largest revenue share in the minimal residual disease testing market in 2021. Cancers that start forming in blood-forming tissue like bone marrow are called hematological malignancies. Lymphoma, multiple myeloma, and leukemia are all types of hematological malignancies. MRD testing using PCR diagnosis enable the identification of cancer cells, including the rare kinds which are detectable in peripheral blood or bone marrow.End-user Outlook
Based on end user, the minimal residual disease testing market is segmented into hospitals & specialty clinics, diagnostic laboratories, academic & research institutions, and others. The academic and research institutions segment garnered a remarkable growth rate in the minimal residual disease testing market in 2021. In academic and research institutions, the MRD test enables the conduction of more studies on rare cancer subjects. In addition, the results of MRD tests can be included as an endpoint in reports focusing on outcomes of clinical trials, which increases their use in clinical practices as well.Regional Outlook
On the basis of region, the minimal residual disease testing market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment procured the highest revenue share in the minimal residual disease testing market in 2021. MRD testing in North America is developing as a result of quick technological advancements, rising R&D expenditures, a developing patent pool along with an increase in applications.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Rad Laboratories, Inc., Guardant Health, Inc., Invitae Corporation (ArcherDX, Inc.), Bio-Techne Corporation, F. Hoffmann-La Roche Ltd., ICON plc (MolecularMD Corporation), Natera, Inc., Sysmex Corporation, Laboratory Corporation of America Holdings, and Invivoscribe, Inc.
Scope of the Study
By Application
- Hematological Malignancies
- Leukemia
- Lymphoma
- Solid Tumors
- Others
By End-user
- Hospitals & Specialty Clinics
- Diagnostic Laboratories
- Academic & Research Institutes
- Others
By Technology
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Flow Cytometry
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Bio-Rad Laboratories, Inc.
- Guardant Health, Inc.
- Invitae Corporation (ArcherDX, Inc.)
- Bio-Techne Corporation
- F.Hoffmann-La Roche Ltd.
- ICON plc (MolecularMD Corporation)
- Natera, Inc.
- Sysmex Corporation
- Laboratory Corporation of America Holdings
- Invivoscribe, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Minimal Residual Disease Testing Market, by Application
1.4.2 Global Minimal Residual Disease Testing Market, by End User
1.4.3 Global Minimal Residual Disease Testing Market, by Technology
1.4.4 Global Minimal Residual Disease Testing Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Global Minimal Residual Disease Testing Market by Application
3.1 Global Hematological Malignancies Market by Region
3.2 Global Leukemia Market by Region
3.3 Global Lymphoma Market by Region
3.4 Global Solid Tumors Market by Region
3.5 Global Others Market by Region
Chapter 4. Global Minimal Residual Disease Testing Market by End User
4.1 Global Hospitals & Specialty Clinics Market by Region
4.2 Global Diagnostic Laboratories Market by Region
4.3 Global Academic & Research Institutes Market by Region
4.4 Global Others Market by Region
Chapter 5. Global Minimal Residual Disease Testing Market by Technology
5.1 Global Polymerase Chain Reaction (PCR) Market by Region
5.2 Global Next-Generation Sequencing (NGS) Market by Region
5.3 Global Flow Cytometry Market by Region
5.4 Global Others Market by Region
Chapter 6. Global Minimal Residual Disease Testing Market by Region
6.1 North America Minimal Residual Disease Testing Market
6.1.1 North America Minimal Residual Disease Testing Market by Application
6.1.1.1 North America Hematological Malignancies Market by Country
6.1.1.2 North America Leukemia Market by Country
6.1.1.3 North America Lymphoma Market by Country
6.1.1.4 North America Solid Tumors Market by Country
6.1.1.5 North America Others Market by Country
6.1.2 North America Minimal Residual Disease Testing Market by End User
6.1.2.1 North America Hospitals & Specialty Clinics Market by Country
6.1.2.2 North America Diagnostic Laboratories Market by Country
6.1.2.3 North America Academic & Research Institutes Market by Country
6.1.2.4 North America Others Market by Country
6.1.3 North America Minimal Residual Disease Testing Market by Technology
6.1.3.1 North America Polymerase Chain Reaction (PCR) Market by Country
6.1.3.2 North America Next-Generation Sequencing (NGS) Market by Country
6.1.3.3 North America Flow Cytometry Market by Country
6.1.3.4 North America Others Market by Country
6.1.4 North America Minimal Residual Disease Testing Market by Country
6.1.4.1 US Minimal Residual Disease Testing Market
6.1.4.1.1 US Minimal Residual Disease Testing Market by Application
6.1.4.1.2 US Minimal Residual Disease Testing Market by End User
6.1.4.1.3 US Minimal Residual Disease Testing Market by Technology
6.1.4.2 Canada Minimal Residual Disease Testing Market
6.1.4.2.1 Canada Minimal Residual Disease Testing Market by Application
6.1.4.2.2 Canada Minimal Residual Disease Testing Market by End User
6.1.4.2.3 Canada Minimal Residual Disease Testing Market by Technology
6.1.4.3 Mexico Minimal Residual Disease Testing Market
6.1.4.3.1 Mexico Minimal Residual Disease Testing Market by Application
6.1.4.3.2 Mexico Minimal Residual Disease Testing Market by End User
6.1.4.3.3 Mexico Minimal Residual Disease Testing Market by Technology
6.1.4.4 Rest of North America Minimal Residual Disease Testing Market
6.1.4.4.1 Rest of North America Minimal Residual Disease Testing Market by Application
6.1.4.4.2 Rest of North America Minimal Residual Disease Testing Market by End User
6.1.4.4.3 Rest of North America Minimal Residual Disease Testing Market by Technology
6.2 Europe Minimal Residual Disease Testing Market
6.2.1 Europe Minimal Residual Disease Testing Market by Application
6.2.1.1 Europe Hematological Malignancies Market by Country
6.2.1.2 Europe Leukemia Market by Country
6.2.1.3 Europe Lymphoma Market by Country
6.2.1.4 Europe Solid Tumors Market by Country
6.2.1.5 Europe Others Market by Country
6.2.2 Europe Minimal Residual Disease Testing Market by End User
6.2.2.1 Europe Hospitals & Specialty Clinics Market by Country
6.2.2.2 Europe Diagnostic Laboratories Market by Country
6.2.2.3 Europe Academic & Research Institutes Market by Country
6.2.2.4 Europe Others Market by Country
6.2.3 Europe Minimal Residual Disease Testing Market by Technology
6.2.3.1 Europe Polymerase Chain Reaction (PCR) Market by Country
6.2.3.2 Europe Next-Generation Sequencing (NGS) Market by Country
6.2.3.3 Europe Flow Cytometry Market by Country
6.2.3.4 Europe Others Market by Country
6.2.4 Europe Minimal Residual Disease Testing Market by Country
6.2.4.1 Germany Minimal Residual Disease Testing Market
6.2.4.1.1 Germany Minimal Residual Disease Testing Market by Application
6.2.4.1.2 Germany Minimal Residual Disease Testing Market by End User
6.2.4.1.3 Germany Minimal Residual Disease Testing Market by Technology
6.2.4.2 UK Minimal Residual Disease Testing Market
6.2.4.2.1 UK Minimal Residual Disease Testing Market by Application
6.2.4.2.2 UK Minimal Residual Disease Testing Market by End User
6.2.4.2.3 UK Minimal Residual Disease Testing Market by Technology
6.2.4.3 France Minimal Residual Disease Testing Market
6.2.4.3.1 France Minimal Residual Disease Testing Market by Application
6.2.4.3.2 France Minimal Residual Disease Testing Market by End User
6.2.4.3.3 France Minimal Residual Disease Testing Market by Technology
6.2.4.4 Russia Minimal Residual Disease Testing Market
6.2.4.4.1 Russia Minimal Residual Disease Testing Market by Application
6.2.4.4.2 Russia Minimal Residual Disease Testing Market by End User
6.2.4.4.3 Russia Minimal Residual Disease Testing Market by Technology
6.2.4.5 Spain Minimal Residual Disease Testing Market
6.2.4.5.1 Spain Minimal Residual Disease Testing Market by Application
6.2.4.5.2 Spain Minimal Residual Disease Testing Market by End User
6.2.4.5.3 Spain Minimal Residual Disease Testing Market by Technology
6.2.4.6 Italy Minimal Residual Disease Testing Market
6.2.4.6.1 Italy Minimal Residual Disease Testing Market by Application
6.2.4.6.2 Italy Minimal Residual Disease Testing Market by End User
6.2.4.6.3 Italy Minimal Residual Disease Testing Market by Technology
6.2.4.7 Rest of Europe Minimal Residual Disease Testing Market
6.2.4.7.1 Rest of Europe Minimal Residual Disease Testing Market by Application
6.2.4.7.2 Rest of Europe Minimal Residual Disease Testing Market by End User
6.2.4.7.3 Rest of Europe Minimal Residual Disease Testing Market by Technology
6.3 Asia Pacific Minimal Residual Disease Testing Market
6.3.1 Asia Pacific Minimal Residual Disease Testing Market by Application
6.3.1.1 Asia Pacific Hematological Malignancies Market by Country
6.3.1.2 Asia Pacific Leukemia Market by Country
6.3.1.3 Asia Pacific Lymphoma Market by Country
6.3.1.4 Asia Pacific Solid Tumors Market by Country
6.3.1.5 Asia Pacific Others Market by Country
6.3.2 Asia Pacific Minimal Residual Disease Testing Market by End User
6.3.2.1 Asia Pacific Hospitals & Specialty Clinics Market by Country
6.3.2.2 Asia Pacific Diagnostic Laboratories Market by Country
6.3.2.3 Asia Pacific Academic & Research Institutes Market by Country
6.3.2.4 Asia Pacific Others Market by Country
6.3.3 Asia Pacific Minimal Residual Disease Testing Market by Technology
6.3.3.1 Asia Pacific Polymerase Chain Reaction (PCR) Market by Country
6.3.3.2 Asia Pacific Next-Generation Sequencing (NGS) Market by Country
6.3.3.3 Asia Pacific Flow Cytometry Market by Country
6.3.3.4 Asia Pacific Others Market by Country
6.3.4 Asia Pacific Minimal Residual Disease Testing Market by Country
6.3.4.1 China Minimal Residual Disease Testing Market
6.3.4.1.1 China Minimal Residual Disease Testing Market by Application
6.3.4.1.2 China Minimal Residual Disease Testing Market by End User
6.3.4.1.3 China Minimal Residual Disease Testing Market by Technology
6.3.4.2 Japan Minimal Residual Disease Testing Market
6.3.4.2.1 Japan Minimal Residual Disease Testing Market by Application
6.3.4.2.2 Japan Minimal Residual Disease Testing Market by End User
6.3.4.2.3 Japan Minimal Residual Disease Testing Market by Technology
6.3.4.3 India Minimal Residual Disease Testing Market
6.3.4.3.1 India Minimal Residual Disease Testing Market by Application
6.3.4.3.2 India Minimal Residual Disease Testing Market by End User
6.3.4.3.3 India Minimal Residual Disease Testing Market by Technology
6.3.4.4 South Korea Minimal Residual Disease Testing Market
6.3.4.4.1 South Korea Minimal Residual Disease Testing Market by Application
6.3.4.4.2 South Korea Minimal Residual Disease Testing Market by End User
6.3.4.4.3 South Korea Minimal Residual Disease Testing Market by Technology
6.3.4.5 Singapore Minimal Residual Disease Testing Market
6.3.4.5.1 Singapore Minimal Residual Disease Testing Market by Application
6.3.4.5.2 Singapore Minimal Residual Disease Testing Market by End User
6.3.4.5.3 Singapore Minimal Residual Disease Testing Market by Technology
6.3.4.6 Malaysia Minimal Residual Disease Testing Market
6.3.4.6.1 Malaysia Minimal Residual Disease Testing Market by Application
6.3.4.6.2 Malaysia Minimal Residual Disease Testing Market by End User
6.3.4.6.3 Malaysia Minimal Residual Disease Testing Market by Technology
6.3.4.7 Rest of Asia Pacific Minimal Residual Disease Testing Market
6.3.4.7.1 Rest of Asia Pacific Minimal Residual Disease Testing Market by Application
6.3.4.7.2 Rest of Asia Pacific Minimal Residual Disease Testing Market by End User
6.3.4.7.3 Rest of Asia Pacific Minimal Residual Disease Testing Market by Technology
6.4 LAMEA Minimal Residual Disease Testing Market
6.4.1 LAMEA Minimal Residual Disease Testing Market by Application
6.4.1.1 LAMEA Hematological Malignancies Market by Country
6.4.1.2 LAMEA Leukemia Market by Country
6.4.1.3 LAMEA Lymphoma Market by Country
6.4.1.4 LAMEA Solid Tumors Market by Country
6.4.1.5 LAMEA Others Market by Country
6.4.2 LAMEA Minimal Residual Disease Testing Market by End User
6.4.2.1 LAMEA Hospitals & Specialty Clinics Market by Country
6.4.2.2 LAMEA Diagnostic Laboratories Market by Country
6.4.2.3 LAMEA Academic & Research Institutes Market by Country
6.4.2.4 LAMEA Others Market by Country
6.4.3 LAMEA Minimal Residual Disease Testing Market by Technology
6.4.3.1 LAMEA Polymerase Chain Reaction (PCR) Market by Country
6.4.3.2 LAMEA Next-Generation Sequencing (NGS) Market by Country
6.4.3.3 LAMEA Flow Cytometry Market by Country
6.4.3.4 LAMEA Others Market by Country
6.4.4 LAMEA Minimal Residual Disease Testing Market by Country
6.4.4.1 Brazil Minimal Residual Disease Testing Market
6.4.4.1.1 Brazil Minimal Residual Disease Testing Market by Application
6.4.4.1.2 Brazil Minimal Residual Disease Testing Market by End User
6.4.4.1.3 Brazil Minimal Residual Disease Testing Market by Technology
6.4.4.2 Argentina Minimal Residual Disease Testing Market
6.4.4.2.1 Argentina Minimal Residual Disease Testing Market by Application
6.4.4.2.2 Argentina Minimal Residual Disease Testing Market by End User
6.4.4.2.3 Argentina Minimal Residual Disease Testing Market by Technology
6.4.4.3 UAE Minimal Residual Disease Testing Market
6.4.4.3.1 UAE Minimal Residual Disease Testing Market by Application
6.4.4.3.2 UAE Minimal Residual Disease Testing Market by End User
6.4.4.3.3 UAE Minimal Residual Disease Testing Market by Technology
6.4.4.4 Saudi Arabia Minimal Residual Disease Testing Market
6.4.4.4.1 Saudi Arabia Minimal Residual Disease Testing Market by Application
6.4.4.4.2 Saudi Arabia Minimal Residual Disease Testing Market by End User
6.4.4.4.3 Saudi Arabia Minimal Residual Disease Testing Market by Technology
6.4.4.5 South Africa Minimal Residual Disease Testing Market
6.4.4.5.1 South Africa Minimal Residual Disease Testing Market by Application
6.4.4.5.2 South Africa Minimal Residual Disease Testing Market by End User
6.4.4.5.3 South Africa Minimal Residual Disease Testing Market by Technology
6.4.4.6 Nigeria Minimal Residual Disease Testing Market
6.4.4.6.1 Nigeria Minimal Residual Disease Testing Market by Application
6.4.4.6.2 Nigeria Minimal Residual Disease Testing Market by End User
6.4.4.6.3 Nigeria Minimal Residual Disease Testing Market by Technology
6.4.4.7 Rest of LAMEA Minimal Residual Disease Testing Market
6.4.4.7.1 Rest of LAMEA Minimal Residual Disease Testing Market by Application
6.4.4.7.2 Rest of LAMEA Minimal Residual Disease Testing Market by End User
6.4.4.7.3 Rest of LAMEA Minimal Residual Disease Testing Market by Technology
Chapter 7. Company Profiles
7.1 Bio-Rad Laboratories, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.2 Guardant Health, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.2.5.2 Product Launches and Product Expansions:
7.3 Invitae Corporation (ArcherDX, Inc.)
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Partnerships, Collaborations, and Agreements:
7.4 Bio-Techne Corporation
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expenses
7.5 F. Hoffmann-La Roche Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Approvals & Trails:
7.6 ICON plc (MolecularMD Corporation)
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Recent strategies and developments:
7.6.4.1 Partnerships, Collaborations, and Agreements:
7.7 Natera Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expenses
7.8 Sysmex Corporation
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expense
7.9 Laboratory Corporation of America Holdings
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental Analysis
7.9.4 Recent strategies and developments:
7.9.4.1 Partnerships, Collaborations, and Agreements:
7.9.4.2 Product Launches and Product Expansions:
7.10. Invivoscribe, Inc.
7.10.1 Company Overview
7.10.2 Recent strategies and developments:
7.10.2.1 Partnerships, Collaborations, and Agreements:
Companies Mentioned
- Bio-Rad Laboratories, Inc.
- Guardant Health, Inc.
- Invitae Corporation (ArcherDX, Inc.)
- Bio-Techne Corporation
- F. Hoffmann-La Roche Ltd.
- ICON plc (MolecularMD Corporation)
- Natera, Inc.
- Sysmex Corporation
- Laboratory Corporation of America Holdings
- Invivoscribe, Inc.
Methodology
LOADING...
